For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Cal-Maine Foods Inc. (CALM) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-07): Designation Watch · Gem Score +18 (−100…+100 Quality+Value blend) · Quality 36 · Value 6 · Sentiment 10 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Cal-Maine Foods Inc.
CALM NASDAQCal-Maine Foods Inc. is the largest producer and distributor of fresh shell eggs in the United States, specializing in the production, grading, packaging, marketing, and distribution of shell eggs, egg products, and prepared foods. Its portfolio includes conventional eggs alongside specialty options such as cage-free, organic, brown, free-range, pasture-raised, and nutritionally enhanced varieties. The company also offers ready-to-eat items like hard-cooked eggs, pre-cooked egg patties, omelets, scrambled eggs, protein pancakes, waffles, crepes, and specialty wraps. Key brands encompass Eggland’s Best, Land O’ Lakes, Farmhouse Eggs, 4-Grain, Sunups, Sunny Meadow, and MeadowCreek Foods, serving a diverse customer base that includes grocery-store chains, club stores, foodservice distributors, retail, and private-label programs. Operating a vertically integrated model with breeder flocks, hatcheries, layer hens, processing plants, and feed mills, Cal-Maine Foods Inc. supports the food sector by providing affordable, high-protein egg-based products nationwide. Founded in 1957 and headquartered in Ridgeland, Mississippi, it plays a pivotal role in the farm products industry within the consumer defensive sector.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 24.95
Total Equity: $2.57B
Shares: 48,891,000
Total Debt: $0.00
Cash: $499.39M
EBITDA: $1.63B
Total Debt: $0.00
Cash: $499.39M
Revenue: $4.26B
Revenue: $4.26B
Revenue: $4.26B
Total Equity: $2.57B
Tax Rate: 24.0%
Equity: $2.57B
Total Debt: $0.00
Cash: $499.39M
Current Liabilities: $308.37M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $2.57B
Shares: 48,891,000
Shares: 48,891,000
CapEx: -$161.26M
Shares: 48,891,000
Stock Price: $81.09
Net Income: $1.22B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 15, 2026 1:06pm (53d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.8B | $3.1B | $2.3B | $4.3B |
| Cost of Revenue | $1.2B | $1.4B | $1.9B | $1.8B | $2.4B |
| Gross Profit | $160.7M | $337.1M | $1.2B | $541.6M | $1.9B |
| Operating Expenses | $186.9M | $193.5M | $228.7M | $229.1M | $314.3M |
| Operating Income | -$26.3M | $143.5M | $967.7M | $312.5M | $1.5B |
| Net Income | $2.1M | $132.7M | $758.0M | $277.9M | $1.2B |
| EBITDA | $33.2M | $211.9M | $1.0B | $392.7M | $1.6B |
| EPS | $0.04 | $2.73 | $15.58 | $5.70 | $25.04 |
| EPS (Diluted) | $0.04 | $2.72 | $15.52 | $5.69 | $24.95 |
Balance Sheet (Annual)
Last updated: Aug 15, 2026 11:40am (53d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $57.4M | $59.1M | $292.8M | $237.9M | $499.4M |
| Total Current Assets | $519.9M | $661.5M | $1.1B | $1.2B | $2.0B |
| Total Assets | $1.2B | $1.4B | $2.0B | $2.2B | $3.1B |
| Current Liabilities | $90.1M | $184.7M | $182.7M | $227.7M | $308.4M |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $216.4M | $323.1M | $344.9M | $387.7M | $518.6M |
| Total Equity | $1.0B | $1.1B | $1.6B | $1.8B | $2.6B |
| Retained Earnings | $976.0M | $1.1B | $1.6B | $1.8B | $2.6B |
Cash Flow (Annual)
Last updated: Aug 15, 2026 1:06pm (53d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $26.1M | $126.2M | $863.0M | $451.4M | $1.2B |
| Capital Expenditure | -$95.1M | -$72.4M | -$136.6M | -$147.1M | -$161.3M |
| Free Cash Flow | -$68.9M | $53.8M | $726.4M | $304.3M | $1.1B |
| Acquisitions (net) | $0 | -$44.8M | $0 | -$53.7M | -$116.2M |
| Net Debt Issued / (Repaid) | $0 | $0 | $0 | $0 | -$2.5M |
| Dividends Paid | -$1.7M | -$6.1M | -$252.3M | -$91.9M | -$330.3M |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | — | — | — | — | — |
Growth Trends (YoY %)
Last updated: Aug 15, 2026 1:06pm (53d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +31.7% | +77.0% | -26.1% | +83.2% |
| Gross Profit Growth | +109.8% | +255.0% | -54.7% | +241.8% |
| Operating Income Growth | +646.5% | +574.2% | -67.7% | +391.8% |
| Net Income Growth | +6,339.3% | +471.4% | -63.3% | +339.0% |
| EBITDA Growth | +538.1% | +390.7% | -62.2% | +315.2% |
Dividend History (Last 20)
Last updated: Aug 15, 2026 11:40am (53d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-04-29 | $0.36 | — | — | — |
| 2026-01-28 | $0.72 | — | — | — |
| 2025-10-29 | $1.37 | — | — | — |
| 2025-08-04 | $2.35 | — | — | — |
| 2025-04-30 | $3.46 | — | — | — |
| 2025-01-29 | $1.49 | — | — | — |
| 2024-10-30 | $1.02 | — | — | — |
| 2024-08-05 | $0.77 | — | — | — |
| 2024-04-30 | $1.00 | — | — | — |
| 2024-01-30 | $0.12 | — | — | — |
| 2023-10-31 | $0.01 | — | — | — |
| 2023-08-04 | $0.76 | — | — | — |
| 2023-04-25 | $2.20 | — | — | — |
| 2023-01-24 | $1.35 | — | — | — |
| 2022-10-25 | $0.85 | — | — | — |
| 2022-07-29 | $0.75 | — | — | — |
| 2022-04-26 | $0.13 | — | — | — |
| 2021-04-27 | $0.03 | — | — | — |
| 2019-04-30 | $0.27 | — | — | — |
| 2019-01-29 | $0.15 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Not computed yetNarrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-17 16:27The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The quarterly trajectory tells the whole story and the synthesis model appears to have missed it. Revenue peaked at $1.42B in the Feb-2025 quarter with a stunning 35.9% net margin, then collapsed sequentially: $1.10B → $922M → $769M → $667M in Feb-2026. Net income compressed from $508M to $50.5M in four quarters — a 90% collapse. Margins went from 35.9% to 7.6%. This is textbook avian-flu-driven price normalization, and the most recent quarter's 7.6% margin is actually *below* Cal-Maine's mid-cycle norm (FY2023 net margin was 24%, FY2024 was 12%, FY2022 was 7.5%, FY2021 was 0.2%). The trailing 12-month earnings that generate the 3.25x PE and $1.22B annual NI are already stale — the runrate now is closer to $200-400M annualized.
The Valuation Synthesis output claiming $212 fair value with "growth is effectively free" is the kind of mechanical DCF error that gives quant models a bad name. Applying no-growth or perpetuity assumptions to a commodity producer at the top of a once-in-a-decade supply-shock cycle is a category error — the Pre-Flight model correctly flagged this ("earnings 10-15x normalized levels"), and Market Forces correctly called it "cycle-peak valuations." The synthesis model and market-forces model directly contradict each other; I side entirely with market-forces. Normalized earnings power for CALM is probably $250-400M annually (blending FY22, FY24, and mid-cycle FY23 partial). At $3.8B market cap, that's 10-15x normalized — reasonable, not cheap, for a no-moat commodity business with mandatory cage-free capex ahead and a 5.9% dividend that is partially variable and will shrink as earnings do.
The contrarian bull case: bird flu keeps recurring (H5N1 has been endemic in wild populations for two years now), the industry structurally under-invests in layer capacity because of ESG/cage-free capex uncertainty, and Cal-Maine's scale plus $499M net cash position lets it consolidate weaker producers into the next shock. The specialty/cage-free mix is genuinely growing and carries better margins. A 6% dividend yield with zero debt and $1.06B FY25 FCF is not nothing — even if FCF halves to $500M, that's still 13% FCF yield. Insider activity is uninformative here (all awards and in-kind tax withholdings, no open-market buying or selling), which the "No Insider Transactions" tag understates — I'd note the absence of insider *buying* on a 31% drawdown is mildly telling for a family-controlled business.
Where the data is thin: we don't have Q3 FY26 egg wholesale prices, we don't have the cage-free capex schedule, and the balance sheet shows total debt as "—" which I'm reading as zero given the 0 debt/equity ratio and 6.38x current ratio. Fair value on normalized $300M NI at 12x = $3.6B, or ~$77/share — remarkably close to current $81. Add back excess cash of ~$400M net of working capital needs and you get maybe $85-90. So the market has this roughly right; the synthesis model's $212-$226 target is fantasy built on peak earnings. I dissent from synthesis, agree with market-forces. The stock is fairly valued to modestly rich given cycle position; the 5.9% dividend is the main reason to own it, and that dividend will compress. No margin of safety, no urgency to buy, no reason to short a debt-free cash generator.
GPT Reading
The raw numbers scream one thing: this is not a cheap compounder at 3.3x earnings, it is a violently cyclical egg-price vehicle being valued on peak or near-peak profits that are already rolling over hard. Quarterly revenue peaked at $1.42B in the February 2025 quarter and has since fallen sequentially to $1.10B, $922.6M, $769.5M, and now $667.0M. Net income has followed the same path from $508.5M to $342.5M to $199.3M to $102.8M to $50.5M, with net margin collapsing from 35.9% to 7.6% in four quarters. That is not a stable “mature earner”; it is a classic commodity downswing. The annual figures tell the same story in bigger print: 2025 revenue of $4.26B and net income of $1.22B were extraordinary versus 2024’s $277.9M and 2023’s $758.0M, and both of those were already far above the 2022 and 2021 earnings base. When a business goes from essentially break-even in 2021 to $1.22B in 2025 with no leverage involved, the first question is not “why is the P/E so low?” but “what is normalized earning power?”
On that question, the market looks much smarter than the valuation model. The model’s $212 fair value is almost certainly capitalizing crisis-era margins as though they were durable. Cal-Maine’s 2025 operating margin was 36.1% and net margin 28.6%; for a shell egg producer, those are windfall economics, not a steady state. Even after the recent drop, if I annualize the latest quarter’s $50.5M of net income I still get about $202M, which would put the stock nearer 19x that run-rate earnings, not 3x. And that $202M may still be above mid-cycle if egg pricing continues to normalize. The company absolutely deserves credit for its balance sheet — $499.4M of cash, zero debt, current ratio above 6x — and for converting the boom into real cash, with $1.06B of free cash flow in 2025. But in a commodity producer, fortress finances protect downside; they do not by themselves justify valuing a peak year as a base year. At $3.80B market cap, investors are paying about 1.5x book and roughly 1.1x net cash-adjusted trailing revenue for a business whose earnings power can move by hundreds of millions of dollars based on egg markets.
What stands out most positively is that this is the best possible version of a bad business model. Cal-Maine appears to be the sector leader, it has no debt, and it did not squander the windfall. If you must own an egg producer, this is the one: 2025 free cash flow covered nearly 28% of today’s market cap, equity stands at $2.57B, and the dividend yield near 5.9% gives some carry while waiting. That matters because commodity cycles can overshoot and re-tighten, especially if avian flu remains disruptive. But those strengths argue for survivability and opportunism, not for taking the trailing multiples at face value. The sequential collapse in sales and profitability is too severe to ignore, and the latest quarter’s 7.6% margin already looks much closer to a normal food producer’s economics than the absurdly high 20%-36% margins seen during the shortage. My read is that the stock is not expensive in a disaster sense, but neither is it obviously cheap simply because the backward-looking screens light up green.
The strongest case against this view is straightforward: even after normalizing down sharply, the stock may still be inexpensive because the balance sheet and cash hoard create a floor, while structural improvement in the mix could mean “normal” margins are higher than history suggests. Revenue in 2025 was not just price; it was also scale, and specialty eggs can support better profitability than legacy commodity assumptions imply. If Cal-Maine can earn even $300M-$400M through the cycle, then $3.80B is only 9.5x-12.5x earnings for a debt-free leader with optionality to consolidate weaker operators. On top of that, 2024 net income was $277.9M before the full 2025 blowout, so the business does not need to repeat $1.22B to justify more than a distressed multiple. I weigh that case less heavily because the near-term evidence is still deteriorating too fast: from $219.1M in the November 2024 quarter to $50.5M five quarters later is not stabilization, it is compression in progress. Without evidence the earnings slide is bottoming, “normalized” estimates can still be too high.
What would change my mind is simple: if the next two quarters show revenue stabilizing around or above $700M and net income holding above roughly $75M-$100M instead of sliding further, I would conclude the company’s post-spike earnings floor is higher than I think and the stock below $85 could be attractive. Likewise, if annual free cash flow remains above $300M even after margins reset, the valuation would start to look genuinely compelling. On the other hand, if quarterly profit drops toward breakeven or low tens of millions, then today’s price is still discounting too little of the comedown and fair value is materially lower.
Grok Reading
The numbers tell a textbook commodity unwind, not a bargain. Cal-Maine just printed a fiscal 2025 that will never repeat in the near term: $4.26B revenue, $1.22B net income, 28.6% net margin, $1.06B free cash flow. Five quarters later the same company is running at a $667M revenue / $50.5M net / 7.6% margin pace, with sequential revenue stepping down $1.42B → $1.10B → $923M → $770M → $667M and margins collapsing 35.9% → 31% → 21.6% → 13.4% → 7.6%. Annualizing the latest quarter produces roughly $2.7B revenue and ~$200M earnings—implying the stock at $81 and a $3.8B market cap is already on ~19x current run-rate earnings, not the 3.25x trailing PE the screen flashes. That trailing multiple is an artifact of avian-flu scarcity rents; using it as a valuation anchor is the classic late-cycle trap. Zero debt, $499M cash, a 6.4 current ratio, and a ~5.9% dividend covered at a 27% payout on boom earnings are real, but they describe a fortress balance sheet attached to a mean-reverting egg price, not a compounder.
The valuation synthesis claiming $212–$226 fair value (+179%) is mechanically consistent with peak-cycle inputs and almost certainly wrong as a forward guide. EV/EBITDA of 2.1x and EV/revenue of 0.81x look absurdly cheap until you remember EBITDA and revenue are mid-air on the way down. Normalize to something closer to the 2022–2024 cluster—call it $250–350M of mid-cycle net income on a $2.3–2.8B revenue base—and the equity is worth roughly $65–100 depending on the multiple a no-growth farm-products leader deserves. At $81 the stock sits inside that band, not 180% below it. Momentum data (83% revenue YoY, 339% earnings YoY) is backward-looking noise from the flu spike; the only growth rate that matters now is the decelerating quarterly trend, which Secondary Signals correctly flags as low revenue confidence. Narrative intensity is minimal for a reason: this trades on flock size, shell-egg quotes, and cage-free capex, not on a durable story.
The strongest case against this read is straightforward and numerate. Opponents will cite the clean balance sheet (debt-to-equity of zero, $1.06B FCF in the last full year), sector-leader scale, 47% ROE and 57% ROIC on the trailing year, and the fact that even after the drawdown the company still cleared 7.6% net margins—well above the near-zero trough of fiscal 2021. They will note that specialty and cage-free mix structurally lifts the floor versus prior cycles, that a 5.9% yield paid by a net-cash company provides a hard total-return ballast, and that every formal valuation method in the packet screams undervalued. They are not wrong that downside is cushioned; I simply weigh the still-unbroken sequential collapse more heavily than trailing returns on capital that were earned at $1.4B quarterly revenue run-rates the company no longer enjoys. A smart bull is buying normalized cash generation plus optionality on the next supply shock; I am not yet convinced the market has mispriced the depth or duration of the current normalization.
Stabilization of quarterly net margins above 10% with revenue holding $700M+ for two consecutive prints would force a re-rating toward the undervalued camp and a higher intrinsic range. Conversely, another leg down through 5% margins or sub-$600M quarterly revenue, or a cut to the dividend, would confirm we are still early in the trough and push the stock toward the low end of book-supported value near the mid-$50s.
Qwen Reading local experiment · off-panel
The quarterly tape tells the whole story, and it is unambiguous: revenue has fallen from $1.42B (March 2025) to $667M (February 2026) in five consecutive quarters, a 53% collapse, while net margin has compressed from 35.9% to 7.6% over the same span. This is not a data glitch or a seasonality artifact — the year-over-year comparison (February 2026 vs. the prior year's comparable quarter) confirms the decline is real. The 2025 fiscal year, with $4.26B revenue and $1.22B net income, was a super-cycle driven by avian-flu supply disruption, and the market is now watching that windfall evaporate in real time. The "Low Revenue Confidence (decelerating)" tag in the secondary signals is the one prior-model output that is correct, and it understates the severity.
The critical error in the prior-model layer is the Valuation Synthesis, which lands on a $212–$226 fair value, 179% above the current $81. That number is only reachable by applying a growth multiple to the 2025 peak earnings of $1.22B as though they were a run-rate. They are not. The five-year annual series shows net income of $2.1M (2021), $132.7M (2022), $758M (2023), $277.9M (2024), and $1.22B (2025) — a range that spans from near-zero to $1.2B in four years. The median of the three "cleaner" years (2022, 2024, and the 2023 figure already inflated by early flu) is roughly $278M, and the most recent two quarters ($102.8M and $50.5M) annualize to about $307M and still falling. A defensible normalized earnings estimate for the next twelve months is $180–$280M, not $1.2B. On that base, the $3.80B market cap implies a P/E of 14–21x, not the 3.25x the canonical metrics display. The 3.25x is a peak-cycle P/E, and for a commodity producer it is the number that looks cheap while being the most misleading number in the dataset.
Building the EV bridge with the trustworthy lines: market cap $3.80B, cash $499.4M, total debt blank (a data gap, but given $2.57B equity and $1.06B peak FCF, a near-zero debt load is plausible for a company that has been aggressively deleveraging through the cycle). EV is approximately $3.30B. Against normalized operating income of roughly $250–$350M (2024 operating income was $312.5M; 2022 was $143.5M), EV/EBITDA sits in the 9–13x range. For a commodity egg producer with no pricing power, extreme earnings cyclicality, and ongoing cage-free capex obligations, that is not a discount — it is the middle of the pack. The 5.93% dividend yield (payout ratio 27%) provides a meaningful floor and signals that management is returning capital rather than over-investing, which is appropriate for a business whose returns on incremental capex are uncertain. The insider transactions are all A-Awards and F-InKind tax withholdings — pure compensation mechanics, zero informational content, and the "No Insider Transactions" tag is technically wrong but substantively neutral.
The strongest case against my "fairly valued" read is the classic cyclical argument: you buy at 3x peak earnings and sell at 20x trough earnings, and the stock at $81 is exactly where a cyclical should be bought. The 2021 trough produced a $2.1M net income on $1.35B revenue; if the cycle fully normalizes to that level, the P/E becomes meaningless and the 5.9% dividend (which would represent a 100%+ payout on trough earnings) becomes unsustainable, forcing a cut that would pressure the stock further. A smart bear would also point to the 2022 operating margin of 8% as the "true" normal, implying normalized NI closer to $130M and a P/E of 29x at current prices — expensive for a commodity. I weigh this differently because the 2022 year was still in the recovery from the 2021 trough, and the 2024 year ($312.5M operating income, 13.4% operating margin) is a more representative "normal" given the company's scale and brand portfolio. The dividend, even if trimmed, still supports a 4–5% yield on a $250M earnings base, which is a real cash floor that a pure commodity peer without Cal-Maine's brand mix would not have.
What would change my mind in either direction: a quarterly print showing net margin stabilizing above 10% for two consecutive quarters would confirm the cycle has bottomed and push me toward undervalued (the 3x peak P/E would then be the entry, not the exit). Conversely, if the next two quarters show revenue below $600M and margin below 5%, the 2021 trough is back on the table, the dividend becomes at risk, and the stock is overvalued at $81. The cage-free capex pipeline is the other swing factor — if the briefing's $161M capex line is the start of a multi-year $1B+ program, free cash flow in normal years drops materially and the 14–21x normalized P/E becomes 20–28x, which is rich. The briefing does not show a multi-year capex schedule, so I cannot price that risk precisely, but it is the single largest threat to the "fairly valued" conclusion.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Cal-Maine is a well-capitalized commodity producer: $499M liquid cash, zero net debt, Altman Z of 9.24, and OCF/NI of 3.48x confirm exceptional balance-sheet integrity and earnings quality. FY2025 delivered $4.26B revenue, 43.4% gross margin, 36.1% operating margin, $1.22B net income and $1.06B FCF - extraordinary numbers, but clearly driven by the avian-flu-fueled egg price cycle. Share count has been essentially flat (48.7M to 48.9M over five years) and SBC is a negligible 0.1% of revenue, so per-share value is fully protected. Accruals of -3% of assets and a Beneish M of -2.05 show no accounting aggression - reported profits are cash-backed. The concern is not integrity but cyclicality: op margin swung from -1.9% (2021) to 30.8% (2023) to 13.4% (2024) back to 36.1% (2025). This is a price-taker in a commodity with no evident moat beyond scale, and the current earnings level almost certainly overstates through-cycle economics. Insider tape shows only awards and tax-withholding events - no open-market buys or sells to read into.
Verify before trusting this (6)
- Through-cycle (10-year) average operating margin and ROIC to normalize away avian-flu pricing
- Capital allocation policy - variable dividend formula, buyback authorization, and M&A pipeline
- Customer concentration (top retailers as % of revenue) from the 10-K
- Specialty/cage-free egg mix and whether it provides any margin stability vs conventional
- Feed cost hedging policy and exposure to corn/soybean input swings
- Whether recent acquisitions (if any) alter the commodity-exposure profile
Price is $81.09 against an e2e composite FV of $212 and signal-adjusted FV of $226 - a 179% upside that is almost certainly a runaway output because the models are anchoring on peak-cycle FY2025 earnings (36% op margin) that will not recur. I discount the anchored-PE of $313 and the DCF of $171 heavily; the EPV floor of $194 is also inflated by cycle earnings. Deserved value has to be built off mid-cycle economics, not the current spike. Mid-cycle, CALM has historically earned $2-4/share in normal years and $10+ in spike years; a blended through-cycle EPS of ~$6-8 at a 12-14x multiple gets you $75-110/share, plus ~$25/share of net cash and investments on the balance sheet. That frames deserved value roughly $95-125 vs a price of $81. So the margin of safety is real but not enormous - roughly 15-40% - and it comes largely from the balance sheet cushion, not from betting that egg prices stay elevated. The bear case (supply normalization, cage-free capex drag, alt-protein) is legitimate but the price already reflects a good chunk of that fade; you are not paying for the spike to continue.
Verify before trusting this (4)
- Current egg futures / USDA layer flock data to gauge how fast prices are normalizing
- Latest net cash / investments balance and any special dividend commitments
- Remaining cage-free conversion capex through 2026-2027
- Management commentary on mid-cycle margin expectations post-HPAI
CALM sits in an unusual sentiment pocket. The macro tape is mildly risk-on (VIX 14, S&P near highs), but with a beta of 0.23 in Consumer Defensive/Farm Products, the tape barely lands on this name either way. Rates at 4.63% and a stretched market PE are a generic drag but not a specific press on a low-duration, cash-generative commodity producer. The active narrative is a late-cycle cyclical story with minimal intensity and fragile durability - meaning the market is not actively re-rating this name in either direction; it is drifting on egg-price prints and avian-flu headlines rather than on a durable thesis. The bear frame (normalizing egg prices, cage-free capex, protein substitution) is the louder whisper, but with low cult and low intensity it is not a dominant force. Recent momentum is the standout: +83% recent versus a 16% long-term CAGR signals that tape flows and shorter-term sentiment have been decisively positive, likely riding sustained egg-price strength and avian-flu supply disruption. That is a real tailwind but a fragile one - the same narrative frame flags it as late-cycle, meaning any print showing supply normalization flips sentiment quickly. Net: modest tailwind from momentum and defensive positioning, offset by a fragile-cyclical overhang and no cult support. Balanced, with a slight positive lean.
Verify before trusting this (4)
- Next USDA egg-price and layer-flock supply prints - the single biggest sentiment lever
- Any avian-flu resolution or fresh outbreak headline - flips the narrative overnight
- Sell-side target revisions after next earnings - late-cycle framing usually shows up as flat-to-down targets despite beats
- Short interest trend - a build would confirm the late-cycle bear is gaining conviction
The world's egg market is oscillating around endemic avian influenza rather than trending. Each outbreak removes supply and spikes price; each recovery floods it and crushes price below cost. Cal-Maine's business is the same physical franchise it was at the peak — the largest US layer flock, low-cost, unleveraged — with the P&L amplitude of a commodity. Layered on top are two slower, real changes: legislated cage-free conversion, which raises the capital intensity of the whole category and favors the operator that can fund it from cash flow, and the shift of consumption toward value-added and prepared egg products, where Cal-Maine has been buying its way into a less price-exposed revenue line. Macro headwinds and a 4.63% 10-year matter little to a food staple with inelastic demand; alternative proteins remain a marginal, not existential, substitution at current egg prices. The honest read: near-term earnings are collapsing off an unrepeatable peak, while the structural earnings power of the asset base is quietly larger than it was before the spike.
Prediction unavailable. valuation-synthesis has no result for CALM — the prediction needs its fair-value anchors.